Posted by

Healthcare companies tend to acquire other entities to expand their products portfolio. Therefore, Mergers and acquisitions (M&A) activities have become common over the last few years [1].  Due to the globalization & companies aiming at expanding their footprints into different geographies, organizations having complex multiple legal entities structure are facing operational challenges with increasing cost and tax structure. A rationalizing approach with an objective to simplify the organizational entities would be to consolidate the different legal entities into a single legal entity [2].

The Most recent M&A activities from the healthcare industry include Pfizer Inc. and GlaxoSmithKline plc announcing their agreement to create a premier global consumer healthcare company with robust iconic brands [3].  & Bristol-Myers Squibb’s agreement on a $74 billion deal to merge with Celgene in a move that will boost its presence in oncology and immunology and make it the fourth-largest drug maker [4].

Read the complete article…

Author Details:

Ashish Vachhani_photoAshish Vachhani

Senior Manager, Regulatory Affairs at FMD K&L Inc

He is a seasoned professional having 13 years of experience in regulatory affairs and has successfully managed multiple projects outsourced by top bio-pharmaceutical, consumer organization. Prior to joining FMD K&L, he worked with prolific companies like Amgen, Glenmark Pharmaceuticals & Torrent Pharmaceuticals undertaking various crucial regulatory roles.